Early Clinical, Imaging, and Pathological Characteristics of SRPK3 / TTN ‐Digenic Myopathy
Open Access
- 14 May 2026
- journal article
- Published by Wiley in Annals of Clinical and Translational Neurology
Abstract
Objective: SRPK3/TTN ‐digenic myopathy was recently established as a skeletal muscle myopathy caused by digenic inheritance. This study characterizes the early clinical presentation of SRPK3/TTN ‐digenic myopathy in one previously reported and seven newly identified pediatric patients. Methods: Next generation sequencing and deep clinical phenotyping provide detailed genetic, clinical, imaging, and histopathological characterization of SRPK3/TTN‐ digenic myopathy. Results: From the cohort of eight male patients (5–19 years at last evaluation), five presented prenatally with reduced fetal movements. At the time of birth, five had hypotonia, two had contractures, and two had respiratory distress. All patients demonstrated motor delay and muscle weakness within the first 15 months of life. Independent ambulation was achieved in six patients (ages 1.5–4 years); three could run. Variable respiratory compromise was documented as early as 5 years of age, with one patient requiring non‐invasive nocturnal ventilation support. Cardiac evaluation was normal in all except one patient who had left ventricular non‐compaction cardiomyopathy. Muscle MRI demonstrated mild, slowly progressive fibroadipose replacement of muscle with striking early selective involvement of the semitendinosus muscle. Histopathologic and ultrastructural features mimicked TTN ‐related myopathy (titinopathy), showing abnormal fiber size variation, increased internally placed nuclei, type 1 fiber predominance, and cores/minicores. Interpretation: This work highlights the early clinical manifestations of SRPK3/TTN ‐digenic myopathy and demonstrates early muscle imaging patterns and histopathological features that are indistinct from those observed in monogenic biallelic titinopathy cases. These features could help with the potentially challenging interpretation of digenic SRPK3 and TTN variants to allow for a confident clinical diagnosis of this novel congenital myopathy.Keywords
Funding Information
- National Heart and Lung Institute (R01 HG009141)
- National Human Genome Research Institute (UM1 HG008900)
- National Institute of Neurological Disorders and Stroke
- Vetenskapsrådet (2021‐02109)
- National Institutes of Health (P50NS053672)
This publication has 32 references indexed in Scilit:
- Congenital Titinopathy: Comprehensive Characterization of the Most Severe End of the Disease SpectrumAnnals of Neurology, 2025
- SRPK3 Is Essential for Cognitive and Ocular Development in Humans and Zebrafish, Explaining X‐Linked Intellectual DisabilityAnnals of Neurology, 2024
- Approaches to Genetic Screening in CardiomyopathiesJACC: Heart Failure, 2023
- Loss of function variants in DNAJB4 cause a myopathy with early respiratory failureActa Neuropathologica, 2022
- Muscle biopsy and MRI findings in ANO5‐related myopathyMuscle & Nerve, 2021
- Making sense of missense variants in TTN-related congenital myopathiesActa Neuropathologica, 2021
- Expanding the importance of HMERF titinopathy: new mutations and clinical aspectsJournal of Neurology, 2019
- Titin‐based mechanosensing modulates muscle hypertrophyJournal of Cachexia, Sarcopenia and Muscle, 2018
- Congenital Titinopathy: Comprehensive characterization and pathogenic insightsAnnals of Neurology, 2018
- Widespread Macromolecular Interaction Perturbations in Human Genetic DisordersCell, 2015